Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
about
Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?Soluble biglycan as a biomarker of inflammatory renal diseases.Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.Review article: monitoring for drug side-effects in inflammatory bowel disease.Five-aminosalicylic Acid: an update for the reappraisal of an old drugReview article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.Management of ulcerative colitis and Crohn's disease.Inflammatory bowel disease: current therapeutic options.5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.The risks and the benefits of mesalazine as a treatment for ulcerative colitis.Renal effects of long-term treatment with 5-aminosalicylic acidMesalazine-induced renal calculi.The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.Drug-induced acute interstitial nephritis.Renal manifestations and complications of inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.5-Aminosalicylic acid, a specific drug for ulcerative colitis.Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatmentChronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.Mesalazine is safe for the treatment of IBD.Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.Development of glomerulonephritis early in the course of Crohn's disease.Mesalazine-induced interstitial nephritis.Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom.5-aminosalicylates in inflammatory bowel disease and chronic renal failure.5-Aminosalicylates and effects on renal function in patients with Crohn's disease.Crohn's disease in a patient with chronic renal failure.
P2860
Q33788444-E6F9F72D-A12B-4CFC-B9CB-A9E049E6A87DQ34160971-40603D71-0364-464A-80B4-58E77B044DF7Q34529943-6E421B9B-0CFC-4764-8939-BC6B53135839Q34585315-0D0D72D4-6D0F-4580-875B-9976F490EE4AQ35061210-E1CB1C43-50B5-4707-9BB4-F99F945BE67CQ35190662-845F78ED-3376-4343-A9AC-036FB43D2B6DQ35595076-B1430965-A4F2-41B5-A171-29F6917B6F1AQ36004867-96335539-2D68-46E7-9B8C-2E124967299EQ36404942-4DEA655E-47A5-4A26-98A7-105487E580E4Q36715466-2D67528E-DB56-42FC-BC25-C8B7AE166626Q36762423-10BB3881-499E-439E-865C-5483389B55C0Q37223156-45FDD8D3-17E5-4C7B-B536-154DBCF4F2ABQ37528584-F6FF023F-8331-4F07-B44E-C71087B3DECAQ37553057-F70B2235-E73B-447F-8CBA-2997D8C16AB3Q37762154-F3EF9DDF-7C21-4539-9AB7-743186837FA3Q37789000-9BF847FC-CB17-4DFE-A1C8-2D95E82EB1EEQ37827164-B4F786DB-FCE9-49D7-B712-87F1DABCFBEFQ38112106-F328282E-BE1D-42C3-B0F2-465B486B2FB2Q38367034-67FE068C-FA08-4F66-85B2-8889609BA033Q38396153-9856373D-8B01-46CB-B8E0-AC8E11D39BFBQ38609002-EF3829A3-8A2A-4A62-AADC-661910DACDD5Q40747451-CD27BAE5-5BFD-43E0-80D2-FA8DC1DB68C5Q43005228-E176B3E8-E731-47AC-B410-08A8070F3CADQ43687351-DD216828-10ED-4D2D-92C7-50C85350DA66Q44712153-FF232530-6FF0-4885-9D90-D287FD284D76Q45917883-56828D14-0201-402A-AEE7-E8F7DB31601DQ46124028-39C4A9D8-AAB8-4F6C-9DE8-691A80C920DBQ46480395-36CBFB7C-012B-4B7A-8C02-28579FC5BBB2Q46707408-AE99E446-C597-4369-9AE6-AE1A775FE919Q46766282-59EE52D5-9CC9-4849-A428-F2CBE7339B52Q53502829-0ADE6558-8726-4859-BF14-EE6C45DC8B57
P2860
Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Review article: interstitial n ...... in inflammatory bowel disease.
@ast
Review article: interstitial n ...... in inflammatory bowel disease.
@en
type
label
Review article: interstitial n ...... in inflammatory bowel disease.
@ast
Review article: interstitial n ...... in inflammatory bowel disease.
@en
prefLabel
Review article: interstitial n ...... in inflammatory bowel disease.
@ast
Review article: interstitial n ...... in inflammatory bowel disease.
@en
P2860
P1476
Review article: interstitial n ...... in inflammatory bowel disease.
@en
P2093
Corrigan G
Stevens PE
P2860
P356
10.1046/J.1365-2036.2000.00683.X
P407
P577
2000-01-01T00:00:00Z